{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T14:39:58Z","timestamp":1773671998798,"version":"3.50.1"},"reference-count":55,"publisher":"American Society for Microbiology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Studies on candidate pandemic vaccines against avian influenza viruses have focused on H5N1, but viruses of other subtypes, such as A\/H9N2, are also considered to have pandemic potential. We investigated the safety and immunogenicity of two immunizations with one of five different antigen doses (ranging from 3.75 to 45 \u03bcg of hemagglutinin antigen) of a nonadjuvanted whole-virus G9 lineage H9N2 influenza virus vaccine in healthy adults aged 18 to 49 years. The antibody responses were measured by hemagglutination inhibition (HI), microneutralization (MN), and single radial hemolysis (SRH) assays. To investigate a hypothesis that previous exposure to H2N2 viruses in subjects born in or before 1968 might prime for more robust antibody responses to H9N2 vaccination than that in subjects born after 1968, a<jats:italic>post hoc<\/jats:italic>age-stratified analysis of antibody responses was done. Both vaccinations in all dose groups were safe and well tolerated. No vaccine-related serious adverse events were reported, and the majority of the adverse reactions were rated as mild. The rates of injection site reactions were lower in the 3.75-\u03bcg- and 7.5-\u03bcg-dose groups than those in the higher-dose groups; the rates of systemic reactions were similar across all dose groups. The seroprotection rates among the different dose groups 21 days after the second immunization ranged from 52.8% to 88.9% as measured by HI assay, from 88.7% to 98.1% or 82.7% to 96.2% as measured by MN assay (MN titer cutoffs, 1:40 and 1:80, respectively), and from 94.2% to 100% as measured by SRH assay. Higher antibody responses were not induced in subjects born in or before 1968. These data indicate that a nonadjuvanted whole-virus H9N2 vaccine is well tolerated and immunogenic in healthy adults. (This study has been registered at<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>under registration no. NCT01320696.)<\/jats:p>","DOI":"10.1128\/cvi.00275-14","type":"journal-article","created":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T04:43:44Z","timestamp":1414644224000},"page":"46-55","source":"Crossref","is-referenced-by-count":11,"title":["Phase I\/II Randomized Double-Blind Study of the Safety and Immunogenicity of a Nonadjuvanted Vero Cell Culture-Derived Whole-Virus H9N2 Influenza Vaccine in Healthy Adults"],"prefix":"10.1128","volume":"22","author":[{"given":"Gerald","family":"Aichinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Grohmann-Izay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maikel V. W.","family":"van der Velden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandor","family":"Fritsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Koska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Portsmouth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Kate","family":"Hart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wael","family":"El-Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otfried","family":"Kistner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. Noel","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","published-online":{"date-parts":[[2014,10,29]]},"reference":[{"key":"key20180919073753_B1","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/S0140-6736(08)60627-3","article-title":"Human infection with highly pathogenic H5N1 influenza virus","volume":"371","year":"2008","journal-title":"Lancet"},{"key":"key20180919073753_B2","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S0140-6736(99)03311-5","article-title":"Human infection with influenza H9N2","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"key20180919073753_B3","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1304459","article-title":"Human infection with a novel avian-origin influenza A (H7N9) virus","volume":"368","year":"2013","journal-title":"N Engl J Med"},{"key":"key20180919073753_B4","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S0140-6736(14)60111-2","article-title":"Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study","volume":"383","year":"2014","journal-title":"Lancet"},{"key":"key20180919073753_B5","volume-title":"Pandemic influenza preparedness and response: a WHO guidance document","author":"World Health Organization","year":"2012"},{"key":"key20180919073753_B6","volume-title":"Responding to the avian influenza pandemic threat: recommended strategic actions","author":"World Health Organization","year":"2012"},{"key":"key20180919073753_B7","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1056\/NEJMoa073121","article-title":"A clinical trial of a whole-virus H5N1 vaccine derived from cell culture","volume":"358","author":"Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team","year":"2008","journal-title":"N Engl J Med"},{"key":"key20180919073753_B8","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1086\/605608","article-title":"A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses","volume":"200","year":"2009","journal-title":"J Infect Dis"},{"key":"key20180919073753_B9","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.vaccine.2011.10.088","article-title":"Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A\/Indonesia\/05\/2005) influenza vaccine","volume":"30","year":"2012","journal-title":"Vaccine"},{"key":"key20180919073753_B10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/infdis\/jit498","article-title":"Safety and immunogenicity of a Vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population","volume":"209","year":"2014","journal-title":"J Infect Dis"},{"key":"key20180919073753_B11","doi-asserted-by":"publisher","first-page":"6127","DOI":"10.1016\/j.vaccine.2012.07.077","article-title":"Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming","volume":"30","year":"2012","journal-title":"Vaccine"},{"key":"key20180919073753_B12","doi-asserted-by":"publisher","first-page":"e17212","DOI":"10.1371\/journal.pone.0017212","article-title":"Phylogenetic diversity and genotypical complexity of H9N2 influenza A viruses revealed by genomic sequence analysis","volume":"6","year":"2011","journal-title":"PLoS One"},{"key":"key20180919073753_B13","doi-asserted-by":"publisher","first-page":"8413","DOI":"10.1128\/JVI.00219-11","article-title":"Phylogeography and evolutionary history of reassortant H9N2 viruses with potential human health implications","volume":"85","year":"2011","journal-title":"J Virol"},{"key":"key20180919073753_B14","doi-asserted-by":"publisher","first-page":"5760","DOI":"10.1128\/JCM.43.11.5760-5767.2005","article-title":"Human infection with an avian H9N2 influenza A virus in Hong Kong in 2003","volume":"43","year":"2005","journal-title":"J Clin Microbiol"},{"key":"key20180919073753_B15","doi-asserted-by":"publisher","first-page":"9654","DOI":"10.1073\/pnas.160270697","article-title":"Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates","volume":"97","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key20180919073753_B16","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.1073\/pnas.1019109108","article-title":"High genetic compatibility and increased pathogenicity of reassortants derived from avian H9N2 and pandemic H1N1\/2009 influenza viruses","volume":"108","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key20180919073753_B17","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1006\/viro.2000.0799","article-title":"H9N2 influenza A viruses from poultry in Asia have human virus-like receptor specificity","volume":"281","year":"2001","journal-title":"Virology"},{"key":"key20180919073753_B18","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.1128\/JVI.02827-06","article-title":"Amino acid 226 in the hemagglutinin of H9N2 influenza viruses determines cell tropism and replication in human airway epithelial cells","volume":"81","year":"2007","journal-title":"J Virol"},{"key":"key20180919073753_B19","doi-asserted-by":"publisher","first-page":"7565","DOI":"10.1073\/pnas.0900877106","article-title":"Minimal molecular constraints for respiratory droplet transmission of an avian-human H9N2 influenza A virus","volume":"106","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key20180919073753_B20","doi-asserted-by":"publisher","first-page":"9372","DOI":"10.1128\/JVI.74.20.9372-9380.2000","article-title":"H9N2 influenza viruses possessing H5N1-like internal genomes continue to circulate in poultry in southeastern China","volume":"74","year":"2000","journal-title":"J Virol"},{"key":"key20180919073753_B21","doi-asserted-by":"publisher","first-page":"e5788","DOI":"10.1371\/journal.pone.0005788","article-title":"Novel genotypes of H9N2 influenza A viruses isolated from poultry in Pakistan containing NS genes similar to highly pathogenic H7N3 and H5N1 viruses","volume":"4","year":"2009","journal-title":"PLoS One"},{"key":"key20180919073753_B22","doi-asserted-by":"publisher","first-page":"8428","DOI":"10.1128\/JVI.00659-09","article-title":"A novel genotype H9N2 influenza virus possessing human H5N1 internal genomes has been circulating in poultry in eastern China since 1998","volume":"83","year":"2009","journal-title":"J Virol"},{"key":"key20180919073753_B23","doi-asserted-by":"publisher","first-page":"e2923","DOI":"10.1371\/journal.pone.0002923","article-title":"Replication and transmission of H9N2 influenza viruses in ferrets: evaluation of pandemic potential","volume":"3","year":"2008","journal-title":"PLoS One"},{"key":"key20180919073753_B24","doi-asserted-by":"publisher","first-page":"12084","DOI":"10.1073\/pnas.1108058108","article-title":"Compatibility of H9N2 avian influenza surface genes and 2009 pandemic H1N1 internal genes for transmission in the ferret model","volume":"108","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key20180919073753_B25","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/S0140-6736(14)60163-X","article-title":"Avian influenza A H10N8\u2013a virus on the verge?","volume":"383","year":"2014","journal-title":"Lancet"},{"key":"key20180919073753_B26","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S0140-6736(14)60386-X","article-title":"Poultry carrying H9N2 act as incubators for novel human avian influenza viruses","volume":"383","year":"2014","journal-title":"Lancet"},{"key":"key20180919073753_B27","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1016\/j.vaccine.2012.04.102","article-title":"A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate","volume":"30","year":"2012","journal-title":"Vaccine"},{"key":"key20180919073753_B28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.vaccine.2009.09.103","article-title":"Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A\/H9N2 vaccine formulations","volume":"28","year":"2009","journal-title":"Vaccine"},{"key":"key20180919073753_B29","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1016\/S0140-6736(03)15014-3","article-title":"Safety and antigenicity of whole virus and subunit influenza A\/Hong Kong\/1073\/99 (H9N2) vaccine in healthy adults: phase I randomised trial","volume":"362","year":"2003","journal-title":"Lancet"},{"key":"key20180919073753_B30","doi-asserted-by":"publisher","first-page":"6028","DOI":"10.1016\/j.vaccine.2007.05.013","article-title":"Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses","volume":"25","year":"2007","journal-title":"Vaccine"},{"key":"key20180919073753_B31","doi-asserted-by":"publisher","first-page":"e9349","DOI":"10.1371\/journal.pone.0009349","article-title":"A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models","volume":"5","year":"2010","journal-title":"PLoS One"},{"key":"key20180919073753_B32","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2307\/2347988","article-title":"Algorithm 183. An efficient and portable pseudo-random number generator","volume":"31","year":"1982","journal-title":"Appl Stat"},{"key":"key20180919073753_B33","first-page":"811","article-title":"Remark AS R58. A remark on algorithm AS 183. An efficient and portable pseudo-random number generator","volume":"121","year":"1985","journal-title":"Appl Stat"},{"key":"key20180919073753_B34","volume-title":"Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials","author":"U.S. FDA","year":"2011"},{"key":"key20180919073753_B35","volume-title":"Guidance for industry: bioanalytical method validation","author":"U.S. FDA","year":"2001"},{"key":"key20180919073753_B36","volume-title":"ICH harmonised tripartite guideline: validation of analytical procedures: text and methodology. Q2(R1)","author":"ICH","year":"2005"},{"key":"key20180919073753_B37","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1128\/JCM.37.4.937-943.1999","article-title":"Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays","volume":"37","year":"1999","journal-title":"J Clin Microbiol"},{"key":"key20180919073753_B38","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1016\/j.vaccine.2012.03.061","article-title":"Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine","volume":"30","year":"2012","journal-title":"Vaccine"},{"key":"key20180919073753_B39","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1056\/NEJMoa0907413","article-title":"Response to a monovalent 2009 influenza A (H1N1) vaccine","volume":"361","year":"2009","journal-title":"N Engl J Med"},{"key":"key20180919073753_B40","doi-asserted-by":"publisher","first-page":"5956","DOI":"10.1016\/j.vaccine.2012.07.039","article-title":"A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memory","volume":"30","year":"2012","journal-title":"Vaccine"},{"key":"key20180919073753_B41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/jama.2009.1911","article-title":"Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial","volume":"303","year":"2010","journal-title":"JAMA"},{"key":"key20180919073753_B42","first-page":"43","article-title":"Single-radial-hemolysis: a new method for the assay of antibody to influenza haemagglutinin. Applications for diagnosis and seroepidemiologic surveillance of influenza","volume":"52","year":"1975","journal-title":"Bull World Health Organ"},{"key":"key20180919073753_B43","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2307\/2533072","article-title":"Order-restricted tests for stratified comparisons of binomial proportions","volume":"52","year":"1996","journal-title":"Biometrics"},{"key":"key20180919073753_B44","doi-asserted-by":"publisher","first-page":"8066","DOI":"10.1016\/j.vaccine.2011.08.044","article-title":"Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine","volume":"29","year":"2011","journal-title":"Vaccine"},{"key":"key20180919073753_B45","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1086\/508174","article-title":"Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A\/H9N2 vaccine preparations","volume":"43","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key20180919073753_B46","doi-asserted-by":"publisher","first-page":"e762","DOI":"10.1542\/peds.2009-2628","article-title":"Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence","volume":"126","year":"2010","journal-title":"Pediatrics"},{"key":"key20180919073753_B47","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.vaccine.2011.12.009","article-title":"Safety and immunogenicity of an MF59-adjuvanted A\/H5N1 pre-pandemic influenza vaccine in adults and the elderly","volume":"30","year":"2012","journal-title":"Vaccine"},{"key":"key20180919073753_B48","doi-asserted-by":"publisher","first-page":"921","DOI":"10.4161\/hv.20248","article-title":"Homologous and heterologous antibody responses to a one-year booster dose of an MF59 adjuvanted A\/H5N1 pre-pandemic influenza vaccine in pediatric subjects","volume":"8","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"key20180919073753_B49","volume-title":"Pandemic influenza vaccine H5N1 Baxter AG: pandemic influenza vaccine (H1N1) (whole virion, inactivated, prepared in cell culture)","author":"EMA","year":"2012"},{"key":"key20180919073753_B50","volume-title":"EPAR summary for the public: Vepacel influenza vaccine (whole virion, inactivated)","author":"EMA","year":"2012"},{"key":"key20180919073753_B51","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1093\/infdis\/jis935","article-title":"Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase","volume":"207","year":"2013","journal-title":"J Infect Dis"},{"key":"key20180919073753_B52","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1128\/JVI.02434-12","article-title":"Neuraminidase-inhibiting antibody is a correlate of cross-protetion against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine","volume":"87","year":"2013","journal-title":"J Virol"},{"key":"key20180919073753_B53","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/infdis\/jir711","article-title":"A Vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies","volume":"205","year":"2012","journal-title":"J Infect Dis"},{"key":"key20180919073753_B54","first-page":"21","article-title":"Developing cell culture-derived pandemic vaccines","volume":"12","year":"2010","journal-title":"Curr Opin Mol Ther"},{"key":"key20180919073753_B55","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1586\/erv.13.21","article-title":"Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development","volume":"12","year":"2013","journal-title":"Expert Rev Vaccines"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.00275-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:51:16Z","timestamp":1627591876000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00275-14"}},"subtitle":[],"editor":[{"given":"S. A.","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,10,29]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,12,30]]},"published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1128\/CVI.00275-14"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00275-14","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,29]]}}}